secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001396814-23-000035
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q2 net income $25.8M; EXPAREL guidance cut to $550-560M
--------------------------------------------------------------

- Total revenue $169.5M flat YoY; EXPAREL net sales $135.1M down from $137.0M.
- GAAP net income $25.8M ($0.51 diluted EPS) vs $19.9M ($0.40) YoY; adjusted EBITDA $54.3M.
- Lowers FY2023 EXPAREL guidance to $550-560M from $570-580M; ZILRETTA to $110-115M.
- Cash $220.8M; operating cash flow $43.5M vs $29.8M YoY.
- Non-GAAP gross margin guidance cut to 73-74% from prior 76-78%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/0001396814-23-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/pcrx-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001396814-23-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer